Table 1.

Prevalence of CVD in all cancer (C00-96) in age groups

Male
Age groups	0–14	15–44	45–54	55–64	65–74	75-	All
LVSD	3.49	0.51	0.84	0.77	1.53	2.20	1.31
LVDD	0.00	0.25	0.56	1.54	1.91	2.41	1.58
LVD	3.49	0.76	1.40	2.31	3.44	4.61	2.89
AF	1.16	0.25	1.26	2.72	4.93	6.71	3.98
IHD	0.00	0.76	1.54	2.31	3.22	3.46	2.46
AS	0.00	0.00	0.00	0.08	0.48	1.20	0.39
VTE	1.16	1.26	1.26	0.65	1.02	1.31	0.98
NT-proBNP	11.63	0.25	0.56	0.85	1.24	3.20	1.36
CVD	12.79	2.78	5.04	7.14	10.44	13.10	8.73
Female
Age groups	0–14	15–44	45–54	55–64	65–74	75-	All
LVSD	5.77	0.13	0.19	0.27	0.40	0.81	0.39
LVDD	0.00	0.20	0.19	0.64	1.45	1.94	0.79
LVD	5.77	0.34	0.38	0.91	1.85	2.75	1.18
AF	3.85	0.00	0.13	0.37	2.40	2.91	1.05
IHD	0.00	0.07	0.06	0.46	0.60	0.97	0.40
AS	0.00	0.00	0.00	0.09	0.75	1.78	0.44
VTE	1.92	0.54	0.38	1.37	1.30	1.13	0.95
NT-proBNP	7.69	0.07	0.25	0.32	1.05	2.10	0.72
CVD	19.23	0.87	0.89	2.97	6.00	7.92	3.53

C00-96 indicates cancer types coded by ICD 10. CVD prevalence in all cancers (from 00 to 96) are derived from the Niigata Cancer Center study (2015). Values in each CVD line are percentages

AF atrial fibrillation, AS aortic stenosis, CVD cardiovascular disease, IHD ischemic heart disease, LVD left ventricular dysfunction, LVDD left ventricular diastolic dysfunction, LVSD left ventricular systolic dysfunction, NT-proBNP N-terminal pro-brain natriuretic peptide, VTE venous thromboembolism